TABLE 1.
The characteristics of the included studies.
| Study | No. of participants | Intervention | Outcomes | |
|---|---|---|---|---|
| Experimental group | Control group | |||
| Meng et al. (2014) | N = 40 (T = 20; C = 20) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Duration of mechanical ventilation, levels of IL-6 at 24 h |
| Guo et al. (2016) | N = 30 (T = 14; C = 16) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Duration of mechanical ventilation |
| Lei et al, 2016) | N = 58 (T = 29; C = 29) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, levels of CK-MB at 72 h |
| Zhou (2017) | N = 80 (T = 40; C = 40) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, levels of CK-MB at 72 h |
| Kawazoe et al. (2017) | N = 201 (T = 100; C = 101) | Dexmedetomidine | Propofol | 28-day mortality, Duration of mechanical ventilation, Incidence of adverse events |
| Ding et al. (2019) | N = 282 (T = 131; C = 152) | Dexmedetomidine | Propofol | ICU stays, Incidence of adverse events, levels of CK-MB at 72 h |
| Liu JQ et al. (2019) | N = 200 (T = 100; C = 100) | Dexmedetomidine | Propofol | 28-day mortality, Duration of mechanical ventilation |
| Wang QS et al. (2019) | N = 101 (T = 42; C = 59) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Incidence of adverse events, levels of IL-6 at 24 h |
| Wang YF et al. (2019) | N = 63 (T = 31; C = 32) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Incidence of adverse events |
| Liu SC et al. (2019) | N = 63 (T = 31; C = 32) | Dexmedetomidine | Propofol | Incidence of adverse events, SOFA, levels of IL-6 at 24 h |
| Xu (2019) | N = 50 (T = 25; C = 25) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Duration of mechanical ventilation, levels of IL-6 at 24 h |
| Cai et al. (2019) | N = 60 (T = 30; C = 30) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Duration of mechanical ventilation, Incidence of adverse events, SOFA |
| Liu Z et al. (2020) | N = 102 (T = 51; C = 51) | Dexmedetomidine | Propofol | 28-day mortality, ICU stays, Duration of mechanical ventilation, SOFA |
| Wei GW et al. (2020) | N = 119 (T = 60; C = 59) | Dexmedetomidine | Propofol | 28-day mortality, Incidence of adverse events |